Citations as recorded by:

1. Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract

Mol. Pharmaceutics, 2017, 14(2) p. 345

DOI: 10.1021/acs.molpharmaceut.6b00641

Citations as recorded by: Cross Ref

2. Novel self-assembled mesalamine–sucralfate complexes: preparation, characterization, and formulation aspects

Drug Development and Industrial Pharmacy, 2016, 42(7) p. 1183

DOI: 10.3109/03639045.2015.1118493

Citations as recorded by: Cross Ref Google

3. What is the real-life maintenance mesalazine dose in ulcerative colitis?

Rev Esp Enferm Dig, 2016, 109

DOI: 10.17235/reed.2016.4620/2016

Citations as recorded by: Cross Ref Google

4. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial

ECCOJC, 2016, 10(8) p. 925

DOI: 10.1093/ecco-jcc/jjw049

Citations as recorded by: Cross Ref PMC Google

5. Combined Diosmectite and Mesalazine Treatment for Mild-to-Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Study

Med Sci Monit, 2015, 21 p. 163

DOI: 10.12659/MSM.891400

Citations as recorded by: Google

6. Huangqin-Tang Ameliorates TNBS-Induced Colitis by Regulating Effector and Regulatory CD4+T Cells

BioMed Research International, 2015, 2015 p. 1

DOI: 10.1155/2015/102021

Citations as recorded by: Cross Ref PMC

7. Huangqin-Tang Ameliorates TNBS-Induced Colitis by Regulating Effector and Regulatory CD4(+) T Cells.

Biomed Res Int, 2015, 2015 p. 1

DOI: 1

Citations as recorded by: Google